Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2023-02-22 Board/Management Inform…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics annonce un remaniement de son Conseil d'Administration et une restructuration de ses effectifs pour se focaliser sur de nouveaux projets
Board/Management Information Classification · 99% confidence The document explicitly announces a 'remaniement de son Conseil d'Administration' (reorganization of the Board of Directors) and a 'restructuration de ses effectifs' (workforce restructuring), including the resignation and replacement of the Chairman and CEO. This content directly aligns with the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2023-02-22 French
Bilan contrat de liquidité au 30122022
Transaction in Own Shares Classification · 98% confidence The document is titled "Bilan au 30 décembre 2022 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont" (Balance sheet as of December 30, 2022, for the liquidity contract with Gilbert Dupont Stock Brokerage Firm). It details the number of shares and cash balance held under a liquidity contract, along with transaction summaries (purchases and sales) for the second half of 2022. This type of regular reporting on share buyback/stabilization activities falls under the category of transactions in the company's own shares (share repurchase/issuance). Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER/MDA: Not an earnings release or management discussion. - DIV: Not a dividend announcement. - CAP: While related to capital, this is specifically about market stabilization/liquidity management, not general fundraising. - POS (Transaction in Own Shares): This definition covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Liquidity contracts are mechanisms used to manage the stock price, often involving the purchase or sale of the company's own shares, making POS the most appropriate fit for this periodic report on liquidity contract activity.
2023-01-05 French
Point d'étape
Regulatory Filings Classification · 95% confidence The document is titled "Point d'étape" (Milestone/Status Update) and provides a current situation update regarding the company's cash position, the decision to stop Phase III studies (FRESH and REFRESH), ongoing discussions for potential mergers/partnerships, and plans for future communication (next update in February 2023). This is not a formal regulatory filing like a 10-K or IR, nor is it a standard Earnings Release (ER) which focuses on financial figures. It is a general operational and strategic update provided to stakeholders. Given the options, this type of strategic status update, especially following major clinical trial news, often falls under general Investor Relations communication. Since there is no specific category for a general 'Status Update', and it is not a formal financial report, it is best classified as a Regulatory Filing (RNS) as a general announcement, or potentially an Investor Presentation (IP) if it were more structured, but its brevity and nature suggest a general regulatory/investor announcement.
2022-12-08 French
Quantum Genomics gives an update
Regulatory Filings Classification · 95% confidence The document is titled "Quantum Genomics gives an update" and is explicitly labeled as a "Press release" dated December 8, 2022. It provides an update on the company's cash position, strategic discussions following negative study results, and future communication plans. This format—a brief, timely announcement of material business developments outside of mandated periodic financial reports (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is an update following a previous announcement and discusses strategic direction and cash position, it functions as an immediate business update, fitting best under the Earnings Release (ER) category, which covers initial announcements of periodical results or significant operational updates. It is too specific for the general RNS fallback, and it is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). Given the context of providing an update on financial status and strategic direction, ER is the most appropriate fit among the specific options.
2022-12-08 English
Quantum Genomics annonce l'annulation de la prochaine réunion de son comité Scientifique et Clinique
Regulatory Filings Classification · 95% confidence The document is a short announcement from Quantum Genomics stating the cancellation of its upcoming Scientific and Clinical Committee meeting scheduled for December 20, 2022. The cancellation is a direct consequence of a prior decision to stop the development of a drug (firibastat) in cardiology. This type of announcement, which communicates a specific operational or strategic change rather than releasing comprehensive financial results (ER, IR, 10-K) or detailing board changes (MANG), fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate announcement that doesn't align with the more specific codes like DIV, CAP, or LTR. Given the short length and the nature of the announcement (a specific operational update), RNS is the most appropriate fallback.
2022-10-31 French
Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments
Regulatory Filings Classification · 95% confidence The document is a press release announcing a significant corporate event: the discontinuation of a Phase III clinical study (FRESH) for a drug (firibastat) due to non-significant efficacy results, and the subsequent redirection of funds. This type of announcement, detailing clinical trial outcomes and strategic shifts, is typically classified as a general corporate update or regulatory filing. It is not a full Annual Report (10-K), an Earnings Release (ER) focusing only on numbers, a formal Audit Report (AR), or a specific management/board change (MANG). Since it is a material announcement that doesn't fit the highly specific categories like DIV, CAP, or DIRS, and it is not merely announcing the publication of another document (RPA), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), which serves as a broad category for material disclosures that don't fit elsewhere. Given the content is a direct announcement of clinical trial results and strategic pivot, RNS is the best fit among the provided options.
2022-10-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.